FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to novel N1-[2,2-dimethyl-1S-(pyridin-2-yl-carbamoyl)-propyl] -N4-hydroxy-2R-isobutyl-3S-methoxysuccinamide or its pharmaceutically acceptable salts, hydrates or solvates. Indicated compounds show biological activity and can be used in medicine for treatment of patients with rheumatic arthritis, malignant neoplasms, cerebrospinal sclerosis or psoriasis. EFFECT: valuable medicinal properties of compounds. 1 cl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYTOSTATIC AGENTS | 1998 |
|
RU2187499C2 |
| DERIVATIVES OF HYDROXAMIC OR CARBOXYLIC ACID AND PHARMACEUTICAL OR VETERINARY COMPOSITION ON SAID | 1995 |
|
RU2136657C1 |
| ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
| ANTIBACTERIAL AGENTS | 1999 |
|
RU2246941C2 |
| DERIVATIVES OF HYDROXAMIC ACID, METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL OR VETERINARY COMPOSITION BASED ON SAID | 1993 |
|
RU2126791C1 |
| PYRROLOPYRIDAZINE DERIVATIVES | 2001 |
|
RU2254335C2 |
| ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446157C2 |
| ETHYLENEDIAMINE DERIVATIVES AND FXa INHIBITOR AND ANTICOAGULANT COMPRISING THEREOF | 2001 |
|
RU2268259C2 |
| COMPOUNDS SUITABLE FOR THERAPY AGAINST HIV | 2019 |
|
RU2806030C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
